Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

Berenberg Maintains Buy on Eli Lilly, Raises Price Target to $375

November 22, 7:17 AM

Berenberg analyst Kerry Holford maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $345 to $375.

March 5, 12:54 PM

Cryptocurrency-focused Silvergate Capital Corp (NYSE: SI) has discontinued the Silvergate Exchange Network, its crypto payments network.

August 31, 7:21 AM

BTIG analyst Eric Hagen downgrades Redwood Trust (NYSE:RWT) from Buy to Neutral.

February 22, 1:29 PM

Morgan Stanley analyst Simeon Gutman maintains Walmart (NYSE:WMT) with a Overweight and lowers the price target from $161 to $160.